CLINDABONE® Oral tablets


Antibiotic.

Recommended for the treatment of infections caused by bacteria sensitive to Clindamycin, such as Staphylococcus, Streptococcus, and anaerobic bacteria as Bacteroides spp., Fusobacterium spp. , Peptoestreptococcus spp., Clostridium perfringens and many species of  Propionibacterium spp. It also presents activity against Toxoplasma gondii. It use is recommended for the treatment of infections caused by bacteria sensitive to Clindamycin in dogs and cats. In dogs, it is recommended as elective therapy for oral infections, pyoderma and osteomyelitis. In cats, it is recommended especially for oral infection treatments. Clindamycin is also recommended in cases of toxoplasmosis in dogs and cats, since allows the improvement of the clinical signs associated with the active infection with Toxoplasma gondii.

Technical Specification

Species


Dogs and cats.

Dosage form


Oral tablets.

Therapeutic action


Antibiotic.

Composition


Each Tablet of 620 mg contains:
Clindamycin Hydrochloride ..............195.04 mg
(Equivalent to 165 mg of basic Clindamycin)
Excipients q.s.p..................................620 mg

Properties


Clindamycin is an antibiotic belonging to the Lincosamide group, which corresponds to a semi-synthetic modification of Lincomycin. It has a spectrum and action similar to Erythromycin, that is, gram positive bacteria, especially staphylococci, streptococci and anaerobic bacteria. Lincosamides are useful for the treatment of infections resistant to Penicillin, Erythromycin and Cephalosporins. Clindamycin inhibits bacterial protein synthesis, altering translocation. It binds to the 50S subunit of the bacterial ribosome, preventing translocation of transfer RNA from site A to site P of the ribosome, preventing the formation of peptide bonds and generating the inhibition of the protein synthesis of the microorganism.

Indications


Recommended for the treatment of infections caused by bacteria sensitive to Clindamycin, such as Staphylococcus, Streptococcus, and anaerobic bacteria as Bacteroides spp., Fusobacterium spp. , Peptoestreptococcus spp., Clostridium perfringens and many species of  Propionibacterium spp. It also presents activity against Toxoplasma gondii. It use is recommended for the treatment of infections caused by bacteria sensitive to Clindamycin in dogs and cats. In dogs, it is recommended as elective therapy for oral infections, pyoderma and osteomyelitis. In cats, it is recommended especially for oral infection treatments. Clindamycin is also recommended in cases of toxoplasmosis in dogs and cats, since allows the improvement of the clinical signs associated with the active infection with Toxoplasma gondii.

Route od administration and dosage


Oral administration.

Active ingredient dose:

The recommended dose for dogs and cats for the treatment of oral infections is: 11 mg/Kg of weight every  24 hours or 5.5 mg/Kg of weight every 12 hours, for 5 days. For the treatment of osteomyelitis in dogs is recommended a dose of 11 mg/Kg of weight every 12 hours, for 28 days. The beginning active dose for the treatment of pyoderma in dogs is 11mg/Kg every 24 hours or 5.5 mg/Kg of weight every 12 hours, for a minimum of 21 consecutive days or at least 7 days after the apparent clinical cure. For the treatment of toxoplasmosis is recommended a dose of Clindamycin for dogs and cats of 10 to 40 mg/Kg and 25 to 50 mg/Kg, respectively, divided into 2 daily doses, for 14 to 21 days.

Product dose:

OraI infections  (Periodontitis):

  • Dogs: ½ Tablet for every 15 Kg of weight twice a day, or 1 tablet for every 15 Kg of weight, once a day for 5 days
  • Cats: ¼ Tablet for every 4 kg of weight, once a day for 5 days. 

Osteomyelitis:

  • Dogs: 1 tablet for every 15 Kg of weight, twice a day for 28 days.

Pyoderma:

  • Dogs: ½ Tablet for every 15 Kg of weight, twice a day or 1 tablet for every 15 Kg of weight, once a day for 21 consecutive days or at least 7 days after the apparent clinical cure.   

Toxoplasmosis:

  • Dogs: 1 tablet for every 10 Kg of weight, twice a day, for 14 to 21 days.
  • Cats: ¼ Tablet for every 2 to 3 Kg of weight, twice a day, for 14 to 21 days.

Drug interactions


  • Lincosamides have a neuromuscular additive effect, when applied with anesthetic agents and relaxants of the skeletal musculature.
  • The association with Kaolin-Pectin does not allow absorption from the gastrointestinal tract.
  • It should not be combined with other bactericidal agents, nor with macrolides, since there may be antagonisms or nephrotoxicity.
  • Cyclosporins: Clindamycin can reduce levels.
  • Erythromycin: antagonism in vitro when administered with Clindamycin.

Contraindications


  • Do not administer in animals with hypersensitivity to Lincomycin and Clindamycin.
  • Do not use in newborn puppies or kittens.
  • Do not administer to cats weighing less than 2 kg.
  • Do not administer concomitantly with other antibiotics such as Chloramphenicol or Macrolides.
  • Do not use in other species than those indicated since their intake can cause serious gastrointestinal disorders.

Precautions


  • In prolonged therapies, the use of probiotics is recommended to maintain the balance of the normal intestinal flora.
  • Use with caution in dehydrated or hypovolemic animals due to the risk of renal toxicity.
  • In case of prolonged treatment with Clindamycin, periodic tests of liver, kidney and blood count should be performed.

Special precautions for the operator


  • Wash hands after administering the product.
  • In case of accidental ingestion, do not induce vomiting, it is recommended to seek immediate medical attention.
  • In case of contact with the eyes, wash with plenty of water for at least 15 minutes.
  • In the case of any type of irritation, it is recommended to go to the doctor.
  • If there is any type of skin irritation, it is recommended to go to the doctor.

Warnings


Keep out of reach of children.

Adverse effects


Prolonged use of Clindamycin may occasionally cause anorexia, vomiting, and diarrhea.

Observations


Use during pregnancy and lactation:
Do not administer to pregnant or lactating females.

Special precautions for the disposal of unused product or waste material:
Discard the remains of unused product in its original container. Do not throw the empty container or with product remains, in rivers, lakes or streams of natural water. Dispose of this product with caution with household waste.

Conservation


Store at a temperature between 15 and 30 ° C, protected from light.

Condition of sale


To be supply only on veterinary prescription.

Presentation


Box containing 20 tablets.

Prepared by


Laboratorio Drag Pharma Chile Invetec S.A.

Records


Chile: Reg. SAG N° 1959-B
Uruguay: Reg. MGAP Nº 2018A00613
Perú: Reg. SENASA F.82.21.I.0448

Countries where it is marketed


Importer in Uruguay by:


VIVAFIL S.A.
RIO NEGRO 1107 Montevideo
Uruguay, TEL 29001112
grupotecnovet@gmail.com
Director Técnico: DMTV Diego Cuadrado.

Imported and Distributed in Peru by:


Representaciones Durand SAC.
Av. Manuel Olguín N° 501 Oficina N° 604
Santiago de Surco Lima.

Imported and distributed in Bolivia by:

ZOOFARMA
TEL: +(591)222-3357
Street Díaz Romero 1339, La Paz.

You have entered drug info or veterinary products intended exclusively (s) kind (s) indicated (s).

Drag Pharma Lab is not responsible for the consequences of misuse of the products, and the use of this information without consulting a veterinarian